Welcome to the e-CCO Library!

OP031: Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s disease: 12-month data from the PANTS study
Year: 2018
Source: ECCO '18 Vienna
Authors:

N.A. Kennedy1*, G. Heap1,2, B. Hamilton1, G.J. Walker1, C. Bewshea1, S. Bouri3, J. Goodhand1, PANTS Investigator Consortium, T. Ahmad1

Created: Thursday, 21 February 2019, 9:14 AM
OP031: Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2 open-label 48-week extension study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Panés J.*1, D'Haens G.R.2, Higgins P.D.R.3, Mele L.4, Moscariello M.4, Chan G.4, Wang W.4, Niezychowski W.4, Su C.4, Maller E.4

Created: Wednesday, 20 February 2019, 10:36 AM
OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandborn W.J.1, Sands B.E.2, Danese S.3, D'Haens G.R.4, Vermeire S.5, Schreiber S.6, Feagan B.7, Reinisch W.8,9, Friedman G.10, Woodworth D.10, Zhang H.10, Lawendy N.10, Niezychowski W.10, Su C.10, Panés J.*11

Created: Wednesday, 20 February 2019, 10:36 AM
OP032: Outcome of pregnancies in female IBD patients treated with vedolizumab
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Moens1,2*, K. van Hoeve2,3, E. Humblet4, J.-F. Rahier5, P. Bossuyt6, S. Dewit7, D. Franchimont8, E. Macken9, J. Nijs10, A. Posen11, A. Van Hootegem12, W. Van Moerkercke13, S. Vermeire1,2, M. Ferrante1,2

Created: Thursday, 21 February 2019, 9:14 AM
OP033: Reduction of tissue pSTAT3 in Crohn's disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vermeire S.*1, De Hertogh G.2, Chen G.3, French D.4, Huntzicker E.4, Van der Aa A.5, Van Kaem T.5, Harrison P.5, Tasset C.5, Galien R.6, Pan Y.4, Feagan B.7, Sandborn W.8

Created: Wednesday, 20 February 2019, 10:36 AM
OP033: The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme
Year: 2018
Source: ECCO '18 Vienna
Authors:

B.E. Sands1, P.R. Taub2, B.G. Feagan3*, A. Armuzzi4, G.S. Friedman5, M. Moscariello5, N. Lawendy5, R.D. Pedersen5, G. Chan5, C.I. Nduaka5, D. Quirk5, L. Salese5, C. Su5

Created: Thursday, 21 February 2019, 9:14 AM
OP034: Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandborn W.J.1, Cyrille M.2, Hansen M.B.3, Feagan B.G.4, Loftus Jr. E.V.5, Rogler G.6, Vermeire S.7, Cruz M.L.2, Yang J.2, Sullivan B.A.2, Reinisch W.*8

Created: Wednesday, 20 February 2019, 10:36 AM
OP034: The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Calafat1,2*, M. Mañosa3,4, F. Cañete3, J. Panés4,5, V. García Sánchez4,6, M. Calvo7, F. Rodríguez-Moranta8, C. Taxonera9, P. Nos4,10, A. López Sanromán11, M.D. Martín Arranz12, M. Mínguez13, J.P. Gisbert4,14, S. García-López15, R. de Francisco16, F. Gomollón4,17, X. Calvet4,18, E. Garcia-Planella19, M. Rivero20, J. Martínez-Cadilla21, F. Argüelles22, L. Arias García23, M. Cimavilla24, Y. Zabana4,25, L. Márquez26, A. Gutiérrez4,27, G. Alcaín28, P. Martínez Montiel29, J. Lázaro30, D. Busquets31, M.F. García Sepulcre32, C. Verdejo33, F. Bermejo34, M. Mora35, D. Monfort36, P. Romero37, B. Velayos38, C. Rodríguez39, A. Rodríguez40, O. Merino41, A. Rodríguez-Pescador42, L. Bujanda4,43, Y. Ber44, M. Vela45, O. Roncero46, J.M. Huguet47, O. García-Bosch48, M. Barreiro-de-Acosta49, R.E. Madrigal50, L. Ramos51, M. Van Domselaar52, P. Almela53, J. Llaó54, A.J. Lucendo4,55, C. Muñoz Vilafranca56, À. Abad57, M. Charro58, J. Legido59, J. Riera1, S. Khorrami60, E. Sesé61, A.M. Trapero62, E. Domènech3,4

Created: Thursday, 21 February 2019, 9:14 AM
OP035: Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandborn W.J.1, Cyrille M.2, Berner Hansen M.3, Feagan B.G.4, Loftus Jr. E.V.5, Vermeire S.6, Cruz M.L.2, Mo M.2, Sullivan B.A.2, Reinisch W.*7

Created: Wednesday, 20 February 2019, 10:36 AM
OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Walker1,2*, J. Harrison3, M. Voskuil4, G. Heap1,2, N. Heerasing1,2, P. Hendy1,2, J. Koskela5,6, M. Daly5,6, H. Sokol7, D. McGovern8, R. Weersma4, C. Bewshea1, M. Weedon3, J. Goodhand1,2, N. Kennedy1,2, T. Ahmad1,2, IBD Pharmacogenetics Study Group

Created: Thursday, 21 February 2019, 9:14 AM
OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with inflammatory bowel disease: a nationwide cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. de Jong1*, S. van Tilburg1,2, L. Nissen2, W. Kievit1, I. Nagtegaal3, F. Hoentjen1, L. Derikx1,2

Created: Thursday, 21 February 2019, 9:14 AM
OP036: Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Costello S.*1,2,3, Waters O.4, Bryant R.2,3, Katsikeros R.3, Makanyanga J.4, Schoeman M.2,3, Mountifield R.5, Tee D.6, Howell S.2, Hughes P.2, Conlon M.7, Roberts-Thomson I.1,2, Andrews J.2,3

Created: Wednesday, 20 February 2019, 10:36 AM
OP037: Infants born to mothers with inflammatory bowel disease exhibit distinct microbiome features that persist up to 3 months of life
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Torres J.*1, Hu J.2, Eisele C.2, Nair N.2, Panchal H.2, Bao X.2, Niu X.2, Côté-Daigneault J.1, Jharap B.1, Maser E.1, Kornbluth A.1, Legnani P.1, George J.1, Dubinsky M.3, Stone J.4, Chen C.-L.4, Clemente J.2,5, Colombel J.-F.1, Peter I.2

Created: Wednesday, 20 February 2019, 10:36 AM
OP037: Risk of cancer in inflammatory bowel disease patients is associated with age and recent use of immunomodulators, while biologics and aminosalicylates are protective factors: a cross-sectional and follow-up analysis of the Swiss IBD cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Greuther1*, S. Scharl1, C. Barthel1, J.-B. Rossel2, L. Biedermann1, B. Misselwitz1, S. Vavricka1, G. Rogler1, M. Scharl1, on behalf of the Swiss IBD Cohort Study Group

Created: Thursday, 21 February 2019, 9:14 AM
OP038: Hobit- and Blimp1-driven tissue resident memory T cells critically control chronic intestinal inflammation
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Zundler1*, E. Becker1, M. Spocinska1, L. Parga-Vidal2, R. Stark2, R. Atreya1, T. Rath1, M. Leppkes1, C. Neufert1, I. Atreya1, K. van Gisbergen2, M.F. Neurath1

Created: Thursday, 21 February 2019, 9:14 AM
OP038: Impact of ileocecal resection in Crohn's disease patients on mucosal microbiota
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Machiels K.*1, Pozuelo del Río M.2, Sabino J.1, Santiago A.2, Campos D.2, Wolthuis A.3, De Buck van Overstraeten A.3, D'Hoore A.3, Van Assche G.1, Ferrante M.1, Rutgeerts P.1, De Hertogh G.3, Vermeire S.1, Manichanh C.2

Created: Wednesday, 20 February 2019, 10:36 AM
OP03: Anti-SARS-CoV2 antibody responses are attenuated in patients with Inflammatory Bowel Disease treated with infliximab
Year: 2021
Source: ECCO'21 Virtual
Authors: Kennedy, N.A.(1);Goodhand, J.(1);Bewshea, C.(1);Nice, R.(2);Chee, D.(1);Lin, S.(1);Chanchlani, N.(1);Butterworth, J.(3);Cooney, R.(4);Croft, N.(5);Hart, A.(6);Irving, P.(7);Kok, K.(8);Lamb, C.(9);Limdi, J.(10);MacDonald, J.(11);McGovern, D.(12);Mehta, S.(13);Murray, C.(14);Patel, K.(15);Pollok, R.(15);Raine, T.(16);Russell, R.(17);Selinger, C.(18);Smith, P.(19);Bowden, J.(20);McDonald, T.(2);Lees, C.(21);Sebastian, S.(22);Powell, N.(23);Ahmad, T.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
OP03: Highly stable epigenome-wide peripheral blood DNA methylation signatures accurately predict endoscopic response to adalimumab, vedolizumab and ustekinumab in Crohn's disease patients: The EPIC-CD study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: JoustraMD., V.(1)*;Li Yim, A.(2,3);Hageman, I.(2);Levin, E.(4);Noble, A.(5);Chapman, T.(6);McGregor, C.(6);Adams, A.(6);Satsangi, J.(6);de Jonge, W.(2);Henneman, P.(3);D'Haens, G.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP03: Inhibition of autophagy exacerbates intestinal fibrosis and EMT
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Cosin-Roger*1,2, D. Ortiz-Masia3, F. Canet1, A. Trescoli-Garcia1, S. Calatayud1, M. D. Barrachina1

Created: Friday, 22 February 2019, 9:41 AM
OP03: Standardized faecal microbiota transplantation with microbiome-guided donor selection in active UC patients: A randomized, placebo-controlled intervention study
Year: 2022
Source: ECCO'22
Authors: Caenepeel, C.(1,2);Deleu, S.(1);Arnauts, K.(1);Vazquez Castellanos, J.F.(3);Braekeleire, S.(1);Machiels, K.(1);Baert, F.(4);Mana, F.(5);Pouillon, L.(6);Hindryckx, P.(7);Lobaton, T.(7);Louis, E.(8);Franchimont, D.(9);Ferrante, M.(1,2);Sabino, J.(1,2);Vieira-Silva, S.(3);Falony, G.(3);Raes, J.(3);Vermeire, S.(1,2);
Created: Friday, 11 February 2022, 3:52 PM